Price inflation penalty rebates established by the Inflation Reduction Act go into effect 1 October for drugs covered by Medicare Part D. But the impact of the provision in the first year may be blunted by the high levels of general inflation now plaguing consumers in the US.
Medicare Part D Price Inflation Rebates Won’t Mean As Much In Inflationary Times
Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.
More from Pricing Debate
More from Market Access
If successful, the new CMS cell and gene therapy access model eventually could expand to oncology or hemophilia products, an Avalere Health expert said.
The much-anticipated report from the US Centers for Medicare and Medicaid Services is heavily redacted and lacks a specific justification for the prices, but preserves agency flexibility to shape the program going forward.
The FDA will stay open, but its rare disease priority review voucher program will wind down after not being renewed on 20 December. PBM reform and other industry priorities also were nixed at the last minute in an effort to avoid a government shutdown.